These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566 [TBL] [Abstract][Full Text] [Related]
6. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism. Díaz L; Martínez-Bonet M; Sánchez J; Fernández-Pineda A; Jiménez JL; Muñoz E; Moreno S; Álvarez S; Muñoz-Fernández MÁ Sci Rep; 2015 Jul; 5():12442. PubMed ID: 26199173 [TBL] [Abstract][Full Text] [Related]
7. Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs. Sánchez-Duffhues G; Vo MQ; Pérez M; Calzado MA; Moreno S; Appendino G; Muñoz E Curr Drug Targets; 2011 Mar; 12(3):348-56. PubMed ID: 20955147 [TBL] [Abstract][Full Text] [Related]
8. Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus. Hori T; Barnor J; Nguyen Huu T; Morinaga O; Hamano A; Ndzinu J; Frimpong A; Minta-Asare K; Amoa-Bosompem M; Brandful J; Odoom J; Bonney J; Tuffour I; Owusu BA; Ofosuhene M; Atchoglo P; Sakyiamah M; Adegle R; Appiah-Opong R; Ampofo W; Koram K; Nyarko A; Okine L; Edoh D; Appiah A; Uto T; Yoshinaka Y; Uota S; Shoyama Y; Yamaoka S Biochem Biophys Res Commun; 2015 Apr; 459(2):288-293. PubMed ID: 25727021 [TBL] [Abstract][Full Text] [Related]
9. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614 [TBL] [Abstract][Full Text] [Related]
10. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877 [TBL] [Abstract][Full Text] [Related]
11. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors. Painter MM; Zaikos TD; Collins KL J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396 [TBL] [Abstract][Full Text] [Related]
12. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages. Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918 [TBL] [Abstract][Full Text] [Related]
13. Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Albert BJ; Niu A; Ramani R; Marshall GR; Wender PA; Williams RM; Ratner L; Barnes AB; Kyei GB Sci Rep; 2017 Aug; 7(1):7456. PubMed ID: 28785069 [TBL] [Abstract][Full Text] [Related]
14. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. Martínez-Bonet M; Clemente MI; Álvarez S; Díaz L; García-Alonso D; Muñoz E; Moreno S; Muñoz-Fernández MÁ Antiviral Res; 2015 Nov; 123():163-71. PubMed ID: 26427554 [TBL] [Abstract][Full Text] [Related]
15. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs. Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A J Virol; 2018 May; 92(10):. PubMed ID: 29343578 [TBL] [Abstract][Full Text] [Related]
16. Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors That Potently Reactivate Latent HIV. Curreli F; Ahmed S; Victor SMB; Debnath AK Viruses; 2020 Jun; 12(6):. PubMed ID: 32503121 [TBL] [Abstract][Full Text] [Related]
17. Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor. Lim H; Kim KC; Son J; Shin Y; Yoon CH; Kang C; Choi BS Virus Res; 2017 Jan; 227():1-5. PubMed ID: 27677464 [TBL] [Abstract][Full Text] [Related]
18. In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation. Brogdon J; Ziani W; Wang X; Veazey RS; Xu H Sci Rep; 2016 Dec; 6():39032. PubMed ID: 27941949 [TBL] [Abstract][Full Text] [Related]
19. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. Jiang G; Mendes EA; Kaiser P; Sankaran-Walters S; Tang Y; Weber MG; Melcher GP; Thompson GR; Tanuri A; Pianowski LF; Wong JK; Dandekar S AIDS; 2014 Jul; 28(11):1555-66. PubMed ID: 24804860 [TBL] [Abstract][Full Text] [Related]
20. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S J Virol; 2018 May; 92(9):. PubMed ID: 29444937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]